Year: 2024
Type: article
Study design: Observational Study
Abstract: Background: The primary objective was to assess the change in oxygenation status of patients after remdesivir treatment.Material and Methods: This retrospective cross-sectional study was conducted at the Aga Khan University Hospital, Karachi from September to December 2020.All patients aged >18 years admitted with a positive reverse transcriptasepolymerase chain reaction for COVID-19 were included.Infection severity was subcategorized into two groups (moderate-to-severe and critical).We compared oxygenation status and assisted ventilation before and after remdesivir treatment.An analysis of outcomes between the groups was conducted using chi squares and the student t-test at a significance level of <0.05.Results: We had 213 COVID-19 patients, of whom 114 (53.5%) received remdesivir during their hospital stay.69 (60.5%) patients were male and the mean age was 52±12 years.56 patients (49.1%) had moderate-to-severe infections.21 out of 56 patients (37.5%) with moderate-to-severe COVID-19 infection while 47 out of 58 patients (81%) with critical COVID-19 required oxygen following remdesivir treatment (p-value: <0.001).Out of 58 critical COVID-19 patients, 46 patients (79.3%) were on non-invasive ventilation and 12 patients (20.7%) were on invasive ventilation prior to remdesivir therapy.22 out of 46 patients (47.8%) recovered from non-invasive ventilation after remdesivir treatment (p-value: <0.001).15 patients had mortality (13.1%) while the mean length of hospital stay with moderate-to-severe COVID-19 infection was 6.8 days and with critical COVID-19 infection was 11.3 days. Conclusion:The study emphasizes that remdesivir was found to be clinically beneficial in patients with moderate-tosevere COVID-19 infection.Besides improving oxygenation status, it also reduced mortality and shortened hospital stays.
Author: Office, Editor
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7218085930
